A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. [electronic resource]
Producer: 20120907Description: 1287-1292 p. digitalISSN:- 1569-8041
- Adult
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Carcinoma
- Cetuximab
- Chemoradiotherapy -- adverse effects
- Cisplatin -- administration & dosage
- Disease Progression
- Disease-Free Survival
- Feasibility Studies
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Nasopharyngeal Carcinoma
- Nasopharyngeal Neoplasms -- pathology
- Neoplasm Recurrence, Local -- therapy
- Neoplasm Staging
- Radiotherapy, Intensity-Modulated -- methods
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article
There are no comments on this title.
Log in to your account to post a comment.